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Background
One of the most promising therapies in persistent and
severe food allergy is oral immunotherapy (OIT), with
immediate goal of desensitization and long-term goal of
tolerance. However, a subgroup of patients may experi-
ence severe allergic reactions. These concerns might be
addressed by combination of OIT with another promis-
ing therapy involving anti-IgE monoclonal antibodies
(omalizumab), which can reduce allergic reactions asso-
ciated with food administration.
Case report
Case1: Female, 16 years, with severe IgE-mediated cow’s
milk allergy (CMA), allergic asthma, rhinitis and
eczema. From 6 months, after the 1st contact with milk,
she suffered multiple anaphylaxis after exposure to hid-
den cow’s milk allergens, despite the restrictive eviction.
She was submitted to milk OIT in day hospital, having
been able to reach 40ml of pure cow milk, with mild
adverse reactions that were controlled. After 1 month of
daily milk intake, she developed persistent abdominal
pain, difficulty breathing and a feeling of tightness neck
that were worsening with angioedema of the face even
with reducing the milk dose to 10ml and under medica-
tion with anti-H1, anti-H2 and montelukast and then
self-suspending milk ingestion. She started omalizumab
225mg SC 2/2 weeks(w) and re-initiated OIT, with oral
ingestion of increasing doses of CM until reaching the
target of 120ml/day and now she eat some milk manu-
factured products(cheese, butter).
Case2: Male, 24 years, with severe IgE-mediated CMA,
with symptoms since the 1st day in maternity hospital
(difficulty breathing after taking the 1st milk aby bottle).
Since then, he had several anaphylactic reactions with
milk traces despite strict diet. He initiated milk OIT
reaching 0.2 ml (dilution 1/10) for 3 weeks. However, he
triggered an anaphylactic reaction controlled with adre-
naline. Then, he started omalizumab 225mg SC 2/2 w
and initiated OIT gradually until 20ml.
Without adverse reactions associated to omalizumab.
Discussion
A successful cow’s milk OIT was possible with the
administration of omalizumab. It showed to be effective
and safe, reducing the risk of severe reactions and
improving the quality of life of pts and their family.
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